The primary purpose of this study is to compare the Clareon/Clareon Toric Intraocular Lenses (IOLs) to the Eyhance/Eyhance Toric IOLs in binocular Best Corrected Distance Visual Acuity (BCDVA) at 3 months postoperative.

This study will enroll adults 22 years of age and older diagnosed with cataracts in both eyes with planned bilateral cataract removal by routine small incision phacoemulsification surgery. Subjects will attend up to 7 scheduled visits: A screening visit, two operative visits, and four post-operative visits. The expected individual duration of participation in the study is 3 months.

Key Inclusion Criteria:

• Planned bilateral cataract removal by routine small incision phacoemulsification surgery;
• Planned implantation of either test or comparator IOL (per randomization) in at least one eye with approximately 1.00 - 3.00 diopter (D) of preoperative corneal astigmatism;
• Predicted postoperative astigmatism of ≤ 0.5 D in both operative eyes based on a Toric calculator;
• Other protocol-specified inclusion criteria may apply.

Key Exclusion Criteria:

• Any disease or pathology, other than cataract, that (in the investigator's opinion) may reduce potential Best Corrected Distance Visual Acuity (BCDVA) to a level worse than 0.2 logarithm minimum angle of resolution (logMAR);
• Clinically significant (in the investigator's opinion) corneal pathology, dry-eye or ocular surface disease that would adversely affect a) the biometry measures and/or toric calculations and b) the visual outcome;
• History of previous intraocular or corneal surgery (including laser-assisted in situ keratomileusis (LASIK));
• Any other planned ocular surgical procedures including but not limited to limbal relaxing incision (LRI), astigmatic keratotomy, LASIK, and retinal laser treatment within the study time frame;
• Other protocol-specified exclusion criteria may apply.

All Implanted Analysis Set (AAS): All eyes with successful study IOL implantation and with at least one postoperative visit.

Adverse events (AEs) were collected from time of consent until study exit. The total expected duration of participation for each subject was approximately 3 months.

AEs were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator. "At Risk" population for ocular AEs is included with unit of "eyes." The Other (Not Including Serious) Adverse Event table reports only the AEs that occurred above a 5% threshold in one or more reporting group. This analysis population includes all eyes with attempted IOL implantation (successful or aborted after contact with the eye) as treated.